Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system
SE Oliver, GA Cloud, PJ Sánchez, GJ Demmler… - Journal of Clinical …, 2009 - Elsevier
BACKGROUND: Ganciclovir protects against hearing deterioration in infants with
symptomatic congenital cytomegalovirus (CMV) disease involving the central nervous
system (CNS). OBJECTIVES: To assess the neurodevelopmental impact of ganciclovir
therapy in this population. STUDY DESIGN: 100 neonates were enrolled into a controlled
Phase III study of symptomatic congenital CMV involving the CNS, and were randomized to
either 6 weeks of intravenous ganciclovir or no treatment. Denver developmental tests were …
symptomatic congenital cytomegalovirus (CMV) disease involving the central nervous
system (CNS). OBJECTIVES: To assess the neurodevelopmental impact of ganciclovir
therapy in this population. STUDY DESIGN: 100 neonates were enrolled into a controlled
Phase III study of symptomatic congenital CMV involving the CNS, and were randomized to
either 6 weeks of intravenous ganciclovir or no treatment. Denver developmental tests were …